Compare BridgeBio Pharma Inc (BBIO) vs Deutsche Bank AG (DB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Deutsche Bank AG — how do they compare? BridgeBio Pharma Inc trades at $84.09 (market cap $16.27B), while Deutsche Bank AG trades at $35.81 (market cap $67.54B). The key difference: Deutsche Bank AG is far larger — about 4.2× BridgeBio Pharma Inc's market cap, and Deutsche Bank AG pays a 3.3% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | DB | |
|---|---|---|
Market Cap | $16.27B | $67.54B |
Sector | Health | Financials |
52-Week High | $90.17 | $40.33 |
52-Week Low | $44.81 | $28.37 |
Enterprise Value | $17.82B | — |
Dividend Yield | — | 3.3% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Deutsche Bank AG
In July 2019, Deutsche Bank announced another restructuring plan hoping to revitalize revenue, reduce costs, and return to profitability. The largest moving pieces of the new plan is the full exit of global equity sales & trading, the scaling back of its fixed income business, as well as 18,000 FTE reductions until 2022. The remaining core business segments include private banking, corporate banking, asset management, and investment banking.
Read more on DB →
